Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials

IMPORTANCE: Primary end point (PEP) changes to an active clinical trial raise questions regarding trial quality and the risk of outcome reporting bias. It is unknown how the frequency and transparency of the reported changes depend on reporting method and whether the PEP changes are associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Florez, Marcus A., Jaoude, Joseph Abi, Patel, Roshal R., Kouzy, Ramez, Lin, Timothy A., De, Brian, Beck, Esther J., Taniguchi, Cullen M., Minsky, Bruce D., Fuller, Clifton D., Lee, J. Jack, Kupferman, Michael, Raghav, Kanwal P., Overman, Michael J., Thomas, Charles R., Ludmir, Ethan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193180/
https://www.ncbi.nlm.nih.gov/pubmed/37195664
http://dx.doi.org/10.1001/jamanetworkopen.2023.13819

Ejemplares similares

Ejemplares similares